Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7198457 versus watchful waiting in ctDNA-positive resected stage II (high risk) and stage III colorectal cancer
2020-000451-12Phase 2Active
- Sponsor
- BioNTech SE
- Start
- Dec 2020
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autogene cevumeran in colorectal cancer (CRC) (2 arms), sponsored by BioNTech SE. Primary endpoint: Disease-free survival. Started Dec 2020; status: active.
02
Drugs
autogene cevumeran
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2020-000451-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000451-12.